Clinical Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma

Abstract This study evaluated the clinical outcomes of first-time micropulse transscleral cyclophotocoagulation (MP-TSCPC) performed in cases of refractory glaucoma. This retrospective study analysed the patients with refractory glaucoma who underwent MP-TSCPC rom February 2018 to February 2020 at Yonsei University Severance Hospital. A total of 45 eyes of 43 Asian patients (aged 55.71±16.84 years) who underwent MP-TSCPC for the first time, were included in this study. The mean baseline intraocular pressure (IOP) was 25.96±9.27 mmHg. The most common diagnosis was secondary glaucoma (44.4%) with a mean logarithm of the minimum angle of resolution (logMAR) visual acuity of 1.19±1.02. There was a significant reduction (P<0.05) in IOP on 1 day 1,to 18.03±5.99 mmHg;, at 1 week, to 13.29±5.24 mmHg;, at 1 month, to 14.98±4.55 mmHg;, at 3 months, to 17.05±5.52 mmHg;, 6 months to 17.78±6.37 mmHg; and 12 months, to 16.56±5.96 mmHg. There was also a reduction (P<0.05) in the number of topical anti-glaucoma medications required to control IOP from baseline (3.69±0.63) at 1, 3, and 6 months. MP-TSCPC is an effective procedure that offers good results in reducing IOP and decreases the use of anti-glaucoma medications in patients with refractory glaucoma.